168 related articles for article (PubMed ID: 37529892)
1. Metastatic non-small-cell lung cancer without driver mutations: projections by therapy line in Western Europe, 2021-2026.
Zhu X; Durbin L; Kanas G; Phiri K; Keeven K; Clark O; Nersesyan K; Aziez A; Stojadinovic A; Bell KF
Future Oncol; 2023 Oct; 19(33):2237-2250. PubMed ID: 37529892
[TBL] [Abstract][Full Text] [Related]
2. The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions.
Campbell D; O'Day K; Hertel N; Penrod JR; Manley Daumont M; Lees M
Popul Health Metr; 2018 Nov; 16(1):17. PubMed ID: 30477516
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and breakdown of non-small cell lung cancer BRAF driver mutations in a large UK cohort.
Lim GHT; Balbi KJ; Poskitt B; Bennett P; Moore DA
Lung Cancer; 2022 Nov; 173():71-74. PubMed ID: 36156323
[TBL] [Abstract][Full Text] [Related]
4. Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.
Dietel M; Savelov N; Salanova R; Micke P; Bigras G; Hida T; Antunez J; Guldhammer Skov B; Hutarew G; Sua LF; Akita H; Chan OSH; Piperdi B; Burke T; Khambata-Ford S; Deitz AC
Lung Cancer; 2019 Aug; 134():174-179. PubMed ID: 31319978
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis.
Van Sanden S; Murton M; Bobrowska A; Rahhali N; Sermon J; Rodrigues B; Goff-Leggett D; Chouaid C; Sebastian M; Greystoke A
Target Oncol; 2022 Mar; 17(2):153-166. PubMed ID: 35226283
[TBL] [Abstract][Full Text] [Related]
6. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
Chen H; Huang D; Lin G; Yang X; Zhuo M; Chi Y; Zhai X; Jia B; Wang J; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
Cancer Med; 2022 Oct; 11(19):3581-3592. PubMed ID: 35394121
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey.
Bailey H; Lee A; Eccles L; Yuan Y; Burlison H; Forshaw C; Varol N
BMC Cancer; 2023 Jun; 23(1):603. PubMed ID: 37386452
[TBL] [Abstract][Full Text] [Related]
8. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
9. Treatment cost of non-small cell lung cancer in three European countries: comparisons across France, Germany, and England using administrative databases.
McGuire A; Martin M; Lenz C; Sollano JA
J Med Econ; 2015; 18(7):525-32. PubMed ID: 25802950
[TBL] [Abstract][Full Text] [Related]
10. Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy.
Labbé C; Leung Y; Silva Lemes JG; Stewart E; Brown C; Cosio AP; Doherty M; O'Kane GM; Patel D; Cheng N; Liang M; Gill G; Rett A; Naik H; Eng L; Mittmann N; Leighl NB; Bradbury PA; Shepherd FA; Xu W; Liu G; Howell D
Clin Lung Cancer; 2017 Jul; 18(4):388-395.e4. PubMed ID: 28111120
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
[TBL] [Abstract][Full Text] [Related]
12. [A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].
Zhang H; Yang X; Li K; Wang J; Lv J; Li X; Zhang X; Qin N; Zhang Q; Wu Y; Ma L; Gai F; Hu Y; Zhang S
Zhongguo Fei Ai Za Zhi; 2021 Feb; 24(2):78-87. PubMed ID: 33478196
[TBL] [Abstract][Full Text] [Related]
13. Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy.
Mountzios G; de Toma A; Economopoulou P; Friedlaender A; Banini M; Lo Russo G; Baxevanos P; Roila F; Banna GL; Christopoulou A; Jimenez B; Collazo-Lorduy A; Linardou H; Calles A; Galetta D; Addeo A; Camerini A; Pizzutilo P; Kosmidis P; Garassino MC; Proto C; Signorelli D; Metro G
Clin Lung Cancer; 2021 Mar; 22(2):e180-e192. PubMed ID: 33162330
[TBL] [Abstract][Full Text] [Related]
14. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
[TBL] [Abstract][Full Text] [Related]
16. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
17. Real-world treatment patterns and clinical outcomes after introduction of immune checkpoint inhibitors: Results from a retrospective chart review of patients with advanced/metastatic non-small cell lung cancer in the EU5.
Slowley A; Phiri K; Multani JK; Casey V; Mpima S; Yasuda M; Chen CC; Manuguid F; Chao J; Aziez A; Bell KF; Stojadinovic A
Thorac Cancer; 2023 Oct; 14(28):2846-2858. PubMed ID: 37592826
[TBL] [Abstract][Full Text] [Related]
18. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
Lim TKH; Skoulidis F; Kerr KM; Ahn MJ; Kapp JR; Soares FA; Yatabe Y
Lung Cancer; 2023 Oct; 184():107293. PubMed ID: 37683526
[TBL] [Abstract][Full Text] [Related]
19. Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis.
Melosky B; Kambartel K; Häntschel M; Bennetts M; Nickens DJ; Brinkmann J; Kayser A; Moran M; Cappuzzo F
Mol Diagn Ther; 2022 Jan; 26(1):7-18. PubMed ID: 34813053
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
